Matches in SemOpenAlex for { <https://semopenalex.org/work/W160073447> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W160073447 endingPage "84" @default.
- W160073447 startingPage "579" @default.
- W160073447 abstract "Several studies are available on the efficacy and safety of 40 kDa branched peginterferon alfa-2a (40-kDa) combined with ribavirin in the treatment of chronic hepatitis C patients. The TeraViC-4 study is a phase III, randomized, parallel group, multicenter study that includes two additional open arms. The main objective is to investigate if extended therapy over 72 weeks increases the rate of sustained virological response induced by a standard 48-week treatment period in naïve patients with chronic hepatitis C who do not show an early virological response. All patients will be treated with peginterferon alfa-2a (40-kDa), 180 micrograms subcutaneous (s.c.) once-weekly, and ribavirin, 400 mg b.i.d. Virological response will be assessed by a hepatitis C virus ribonucleic acid (HCV-RNA) qualitative polymerase chain reaction (PCR) test. Non-early responders (HCV-RNA still detectable after 4 weeks of therapy) will be randomly separated to receive combination therapy for 44 or 68 additional weeks. Early responders (undetectable HCV-RNA at week 4) will be allocated into two open arms according to HCV genotype and basal viral load, and they will be treated for 20 or 44 additional weeks. All patients will be followed for 24 weeks on no therapy. A total of 504 patients are planned to be included in the study in order to reach the required sample size in the two randomized groups. Efficacy of treatment will be assessed by determination of HCV-RNA and the primary efficacy variable is the rate of sustained virological response (after 24 weeks of treatment-free follow-up) in patients without early virological response. Secondary efficacy variables are the rate of sustained biochemical response, the rate of response in function of HCV genotype, viral load and treatment duration. Safety data will also be recorded and analyzed." @default.
- W160073447 created "2016-06-24" @default.
- W160073447 creator A5001994267 @default.
- W160073447 creator A5015512320 @default.
- W160073447 creator A5034050756 @default.
- W160073447 creator A5061689613 @default.
- W160073447 creator A5076411761 @default.
- W160073447 creator A5079238747 @default.
- W160073447 date "2002-11-01" @default.
- W160073447 modified "2023-09-27" @default.
- W160073447 title "Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4." @default.
- W160073447 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12616704" @default.
- W160073447 hasPublicationYear "2002" @default.
- W160073447 type Work @default.
- W160073447 sameAs 160073447 @default.
- W160073447 citedByCount "2" @default.
- W160073447 crossrefType "journal-article" @default.
- W160073447 hasAuthorship W160073447A5001994267 @default.
- W160073447 hasAuthorship W160073447A5015512320 @default.
- W160073447 hasAuthorship W160073447A5034050756 @default.
- W160073447 hasAuthorship W160073447A5061689613 @default.
- W160073447 hasAuthorship W160073447A5076411761 @default.
- W160073447 hasAuthorship W160073447A5079238747 @default.
- W160073447 hasConcept C126322002 @default.
- W160073447 hasConcept C142462285 @default.
- W160073447 hasConcept C168563851 @default.
- W160073447 hasConcept C203014093 @default.
- W160073447 hasConcept C2522874641 @default.
- W160073447 hasConcept C2776235749 @default.
- W160073447 hasConcept C2776408679 @default.
- W160073447 hasConcept C2780040827 @default.
- W160073447 hasConcept C71924100 @default.
- W160073447 hasConcept C90924648 @default.
- W160073447 hasConceptScore W160073447C126322002 @default.
- W160073447 hasConceptScore W160073447C142462285 @default.
- W160073447 hasConceptScore W160073447C168563851 @default.
- W160073447 hasConceptScore W160073447C203014093 @default.
- W160073447 hasConceptScore W160073447C2522874641 @default.
- W160073447 hasConceptScore W160073447C2776235749 @default.
- W160073447 hasConceptScore W160073447C2776408679 @default.
- W160073447 hasConceptScore W160073447C2780040827 @default.
- W160073447 hasConceptScore W160073447C71924100 @default.
- W160073447 hasConceptScore W160073447C90924648 @default.
- W160073447 hasIssue "9" @default.
- W160073447 hasLocation W1600734471 @default.
- W160073447 hasOpenAccess W160073447 @default.
- W160073447 hasPrimaryLocation W1600734471 @default.
- W160073447 hasRelatedWork W1824848373 @default.
- W160073447 hasRelatedWork W1975507313 @default.
- W160073447 hasRelatedWork W1983458327 @default.
- W160073447 hasRelatedWork W1984864596 @default.
- W160073447 hasRelatedWork W2007217713 @default.
- W160073447 hasRelatedWork W2072969050 @default.
- W160073447 hasRelatedWork W2115499251 @default.
- W160073447 hasRelatedWork W2145291317 @default.
- W160073447 hasRelatedWork W2147954883 @default.
- W160073447 hasRelatedWork W2412286968 @default.
- W160073447 hasVolume "24" @default.
- W160073447 isParatext "false" @default.
- W160073447 isRetracted "false" @default.
- W160073447 magId "160073447" @default.
- W160073447 workType "article" @default.